// App-Quantinova.ai

P218 2016 HTN : Induction of Human Endothelin-1 Overexpression for 3 Months Causes Blood Pressure Rise and Small Artery Endothelial Dysfunction and Stiffening

Researchers

Presenter

  • Sofiane Ouerd

Principal Investigators

  • Julio C. Fraulob-Aquino

  • Tlili Barhoumi

  • Stefan Offermanns

  • Pierre Paradis

  • Ernesto L Schiffrin

Medical Centers

  • McGill Univ, Sir Mortimer B. Davis-Jewish General Hosp, Lady Davis Inst for Medical Res and Dept of Med, Vascular and Hypertension Res Unit, Montreal, QC, Canada

  • McGill Univ, Sir Mortimer B. Davis-Jewish General Hosp, Lady Davis Inst for Medical Res and Dept of Med, Vascular and Hypertension Res Unit, Montreal, QC, Canada

  • Dept of Pharmacology, Max-Planck-Inst for Heart and Lung Res, Bad Nauheim, Germany

  • McGill Univ, Sir Mortimer B. Davis-Jewish General Hosp, Lady Davis Inst for Medical Res and Dept of Med, Vascular and Hypertension Res Unit, Montreal, QC, Canada

Locations

  • Canada

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

Disease

  • Vasodilation dysfunction

  • Acute renal failure

Biomarkers

  • Proto-oncogene tyrosine-protein kinase ROS

  • Endothelin-1

Drug/Treatment

  • Acetylcholine

  • endothelin-1

  • atrasentan

  • Tamoxifen

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved